Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

The FDA has granted zongertinib (HERNEXEOS, Boehringer Ingelheim Pharmaceuticals, Inc.) a first-line indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer ...

In this analysis from the phase 3 EMPOWER‐Lung 1 study, researchers reported on quality of life in patients with advanced non‐small cell lung cancer and PD-L1 expression of 50% or more.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

(A) NKAPL expression levels in human lung cancer cell lines (A549, H1299, H358, NCI-H446, NCI-H460, NCI-H2122, NCI-H1651, CHAGO-K-1, and SW1271) and normal lung tissues (#1, #2) were detected via ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK ...

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...